Almost all AML cells and leukemic stem cells express CD33 at high levels, whereas normal cells express it at low levels, even at low effector-to-target ratios of < 1:20, making CD33 a useful diagnostic marker and therapeutic target for AML. The gene discussed is CD33; the disease is acute myeloid leukemia.